literature

HIV mutation literature information.

Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.

PMID: 24079831 2013 Biochemistry

5Result: Another multi-drug resistant mutant, MDR769 (PDB accession code ITW7) which exhibits a pronounced ""wide-open"" conformation of both flaps, also contains several of the substitutions seen in PR20: namely, S37N, I62V, I63P, A71V, I84V, and L90M."

Result: Mutations defined as major DRMs associated with DRV and saqunavir (SQV) resistance are 147V, I54L, I84V (DRV), and L90M (SQV).

Result: The DRM, ANAM-11, bears six mutations identical or similar to PR20 (L10I/F, M36I, L63P,

Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina.

PMID: 24093951 2013 Journal of the International AIDS Society

Method: Sequences were analyzed to identify mutations associated with reduced susceptibility to protease and RT inhibitors, as reported by the International AIDS Society-USA in 2010: RT-M41L, A62V, K65R, D67N, 69 insert, K70R, L74V,V75I, F77L, L100I, K101P, K103N, V106A, V106M, V108I, Y115F, F116Y,

Description of HIV-1 group M molecular epidemiology and drug resistance prevalence in Equatorial Guinea from migrants in Spain.

PMID: 23717585 2013 PloS one

Result: The PI-resistance mutations found were M46L (4 cases), and L90M and I84V (3 cases each).

Table: I84V

Potential elucidation of a novel CTL epitope in HIV-1 protease by the protease inhibitor resistance mutation L90M.

PMID: 24015196 2013 PloS one

Method: Equations 1, 2, 3, 4 and 5 represent L90M frequency estimators trained from the V82A, I54V, A71V, M46I and I84V sets respectively.

Result: Five sequence sets were constructed, each devoid of M46I, I54V, V71A, V82A and I84V respectively, which were

Table: I84V

Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China.

PMID: 24009694 2013 PloS one

Table: I84V

Persistence of HIV-1 transmitted drug resistance mutations.

PMID: 23904291 2013 The Journal of infectious diseases

Table: I84V

Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.

PMID: 23792096 2013 Biochemical and biophysical research communications

Abstract: Mutations at residues 32I, L33F, 46I, 47A, I54V, V82A, I84V, and L90M render the protease drug resistant against LPV.

Introduction: Although drug resistance is relatively less likely to develop against LPV compared to other HIV-1 protease inhibitors, resistance mutations, including 32I, 47A, 46I, L33F, I54V, V82A, I84V, and L90M, or combinations among L76V, M46I, and V82A in the protease, and A431V

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

PMID: 23840622 2013 PloS one

Method: The following non-polymorphic ARV-selected mutations were classified as drug resistance mutations (DRM): (i) the NRTI resistance mutations M41L, A62V, K65RN, D67NG, T69D, T69 insertions, T69 deletion, K70REGQ, L74VI, V75MT, F77L, Y115F, F116Y, Q151M, M184VI, L210W, T215YFSDCIV, and K219QENR; (ii) the

Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay.

PMID: 23985909 2013 Journal of clinical microbiology

Abstract: All the wild-type and mutant alleles were unequivocally distinguished with plasmid templates, and the limits of detection were 1.56% for K219Q and K219E, 3.13% for L76V, 6.25% for K65R, K70R, L74V, L100I, K103N, K103R, Q151M, Y181C, and I47V, and 12.5% for M41L, K101P, K101E, V106A, V106M, Y115F, M184V,

PMID: 22237471 2012 Infection

Abstract: DISCUSSION: The higher statistical difference at baseline between failing versus non-failing patients was observed for the V32I and I84V mutations.

Browser Board

Co-occurred Entities

Filtrator